Treatment‐free remission in <scp>CML</scp> patients with additional chromosome abnormalities in the Philadelphia‐positive clone or variant Philadelphia translocations-Reference-Cited by-同舟云学术

Treatment‐free remission in CML patients with additional chromosome abnormalities in the Philadelphia‐positive clone or variant Philadelphia translocations

Published:2024-03-04 Issue:6 Volume:99 Page:1172-1174
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Claudiani Simone¹²^ORCID,Chee Lynette³,Fernando Fiona¹²,Brown Loretta⁴,Achandira Udayakumar M.⁴,Khan Afzal¹²,Rothwell Kate⁵,Hayden Chloe⁶,Koutsavlis Ioannis⁷,Hannah Guy⁸,Innes Andrew¹²^ORCID,Apperley Jane F.¹²,Milojkovic Dragana¹²

Affiliation:

1. Department of Haematology, Hammersmith Hospital Imperial College Healthcare NHS Trust London UK

2. Centre for Haematology, Department of Immunology and Inflammation, Faculty of Medicine Imperial College London London UK

3. Department of Clinical Haematology Peter MacCallum Cancer Centre and the Royal Melbourne Hospital Melbourne Victoria Australia

4. Department of Molecular Pathology, Hammersmith Hospital Imperial College Healthcare NHS Trust London UK

5. Department of Clinical Haematology Leeds Teaching Hospital NHS Trust Leeds UK

6. Imperial Molecular Pathology, Hammersmith Hospital Imperial College Healthcare NHS Trust London UK

7. Hematology Department Western General Hospital Edinburgh UK

8. King's College Hospital NHS Foundation Trust Department of Haematological Medicine London UK

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27278

Reference11 articles.

1. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

2. Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

3. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

4. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

5. Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment‐free remission in chronic myeloid leukemia;American Journal of Hematology;2024-03-28